The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | Key factors guiding CAR-T vs bispecific selection in FL: clinical and patient considerations
Juan Alderuccio, MD, Sylvester Comprehensive Cancer Center, Miami, FL, discusses treatment selection between CAR T-cell therapy and bispecific antibodies for follicular lymphoma (FL), emphasizing the lack of randomized data favoring either approach. Dr Alderuccio highlights prior bendamustine exposure as a key consideration due to its potential impact on CAR-T efficacy, with patient preferences helping to guide treatment decisions. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
